focus -WSS

focus

author：focus 2025-10-02 21:33:06 - browse：68527

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

WSS

Can gargling with Listerine treat gonorrhea of the mouth?

AltruBio raises $225 million to develop ulcerative colitis drug

ACIP vaccine advisory panel sees its vacancies filled

BIO to announce reorganization, senior leaders expected to depart

As billionaires fund anti

Abbott's new heart device gets FDA advisory panel nod

Wikipedia

focus

leisure time

Medicare details structure of new drug price negotiation program

Study gives hint on South Asians’ higher risk of cardiovascular disease

Wildfire smoke exposes gaps in outdoor worker protections

Too many hospitalized Covid

Jerome Adams on the need for new antivirals for Covid

ACIP vaccine advisory panel sees its vacancies filled

BioMarin wins approval for gene therapy to treat hemophilia A

Novel spinal cord stimulator treats paralysis without surgery

Jerome Adams on the need for new antivirals for Covid

The creative science of coining drug names

entertainment

Long Covid research funding gets a major boost from NIH

Primary care doctor shortage won't be solved by free med school tuition

Brain technologies pose threats that are all too real, experts warn

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Why Eli Lilly’s earnings didn’t quite live up to the hype

Report cites 'urgent' need to recruit more diverse clinical trial participants

focus

focus

hotspot

explore